Cognition Therapeutics, Inc. operates as a biopharmaceutical company. The Company discovers and develops small molecule therapeutics targeting toxic proteins that cause cognitive decline associated with alzheimer's disease and other degenerative diseases of the human brain. Cognition Therapeutics serves customers worldwide.